Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Page Menu

Charles R Kiefer

UMassMed Faculty Page

Inventions:

Title: Anti-fracCRP Hybridomas and Monoclonal Antibodies. UMMS13-71; Patent Pending. 

  • This invention provides antibodies and antibody fragments that bind to human fractional C-Reactive Protein (fracCRP), kits and assays using these antibodies and antibody fragments to diagnose low to moderate risk for Acute Coronary Syndrome (ACS). This invention is based on two clinical studies (one prospective, one retrospective) that measured fracCRP, Troponin I (TnI), and the fracCRPxTnI metric on 210 patients (105 each with final diagnoses of ACS negative or ACS positive). Overall, the method demonstrated strong diagnostic rule-in value for these patients on arrival, with a specificity of 96.2%, positive predictive value of 91.7%, sensitivity of 41.9%, and negative predictive value of 62.3%. 

Title: FRACTIONAL C-REACTIVE PROTEIN (FRACCRP) ANTIBODIES AND ASSAYS. UMS10-49; Patent 9,841,430.

  • This invention discloses antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments to assess patients at low to moderate risk for Acute Coronary Syndrome (ACS). Overall, this method demonstrated strong diagnostic rule-in value for these patients, with a specificity of 96.2%, positive predictive value of 91.7%, sensitivity of 41.9%, and negative predictive value of 62.3%. 

Title: METHODS FOR EARLY DIAGNOSIS OF ACUTE CORONARY SYNDROME. UMMS08-26; Patent 9,116,155

  • This innovation provides a method to assess acute tissue damage and stratify acute coronary syndrome. Analysis of circulating C-reactive protein (CRP) and fractional forms of CRP (fracCRP), permits early measurement of tissue damage than fracCRP values only in a specific diseases context previous inventions, thus, broadening the scope of application for this established laboratory value.  of the use of fraCRP values. This process provides a method for a more comprehensive analysis of acute tissue damage that may be applicable to a variety of clinical scenarios.

  

Innovation TopicsDiagnosticsCardiovascular disease/CardiologyAcute Coronary Syndrome (ACS)AntibodyC-reactive proteinTroponinAtherosclerosisIschemia